Accordingly, in tumors structural disruption of TP63 and aberrant p63 expression are commonly seen in squamous cell and transitional cell carcinomas, but are also observed in non-Hodgkin lymphomas, predominantly in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (grade 2 and 3) [25–30]. The gene discussed is TP63; the disease is diffuse large B-cell lymphoma.